mAb114, which is one of the two treatments that showed some efficacy in the recent Ebola trial conducted in the Congo by NIH, and a pan-influenza-A antibody that recognizes every strain of Flu A that has arisen since the 1918 pandemic and will start Phase 2 trials for flu prophylaxis later this year. A number of years ago, we had isolated antibodies from survivors of the SARS-1 epidemic. When SARS-CoV-2 emerged, we went back to those SARS-1 antibodies to assess whether any of them were capable of cross-reacting with SARS-CoV-2. And of course we also screened antibodies from patients who
...more
